Table 1.
Baseline characteristics of study participants in intervention and control groups.
| Participant characteristic | Treatment-naive | Treatment-experienced | ||
|---|---|---|---|---|
| Intervention (n = 52) | Control (n = 51) | Intervention (n = 46) | Control (n = 47) | |
| Sex (%) | ||||
| Male | 24 (46.2) | 27 (52.9) | 22 (47.8) | 21 (44.7) |
| Female | 28 (53.8) | 24 (47.1) | 24 (52.2) | 26 (55.3) |
| Age group (years) | ||||
| 20–40 | 38 (73.1) | 39 (76.5) | 32 (69.6) | 34 (72.3) |
| >40–60 | 14 (26.9) | 10 (19.6) | 13 (28.3) | 13 (27.6) |
| >60 | 0 (0.0) | 2 (3.9) | 1 (2.2) | 0 (0.0) |
| Ethnicity (%) | ||||
| Han | 41 (78.8) | 49 (96.1) | 41 (89.1) | 40 (85.1) |
| Other | 11 (21.2) | 2 (3.9) | 5 (10.9) | 7 (14.9) |
| Marital status (%) | ||||
| Single | 3 (5.8) | 2 (3.9) | 3 (6.5) | 2 (4.3) |
| Married/cohabiting | 44 (84.6) | 46 (90.2) | 41 (89.1) | 39 (83.0) |
| Divorced/widowed | 5 (9.6) | 3 (5.9) | 2 (4.3) | 6 (12.8) |
| Education level (%) | ||||
| None | 4 (7.7) | 3 (5.9) | 3 (6.5) | 3 (6.4) |
| Primary school | 21 (40.4) | 24 (47.1) | 14 (30.4) | 18 (38.3) |
| Junior high school | 24 (46.2) | 19 (37.3) | 22 (47.8) | 20 (42.6) |
| High school or above | 3 (5.8) | 5 (9.8) | 7 (15.2) | 6 (12.8) |
| Occupation (%) | ||||
| Agriculture | 44 (84.6) | 41 (80.4) | 37 (80.4) | 37 (78.7) |
| Business | 6 (11.5) | 7 (13.7) | 3 (6.5) | 2 (4.3) |
| Other | 2 (3.8) | 3 (5.9) | 6 (13.0) | 8 (17.0) |
| Residential area (%) | ||||
| Rural | 47 (90.4) | 48 (92.3) | 39 (84.8) | 43 (91.5) |
| Urban | 5 (9.6) | 4 (7.7) | 7 (15.2) | 4 (8.5) |
| Annual income (CNY)a | ||||
| <2000 | 22 (42.3) | 18 (35.3) | 14 (30.4) | 9 (19.1) |
| 2000–10000 | 21 (40.4) | 15 (29.4) | 24 (52.2) | 31 (66) |
| >10000 | 9 (17.3) | 18 (35.3) | 8 (17.4) | 7 (14.9) |
| Transmission route (%) | ||||
| Heterosexual | 46 (88.5) | 42 (82.4) | 43 (93.5) | 44 (93.6) |
| Injecting drug use | 6 (11.5) | 8 (15.7) | 2 (4.3) | 5 (10.6) |
| Other | 4 (7.7) | 8 (15.7) | 1 (2.2) | 1 (2.1) |
| CD4 count (cells/mm3) | ||||
| ≤100 | 12 (23.1) | 9 (17.6) | 2 (4.4) | 1 (2.2) |
| >100–200 | 13 (25.0) | 10 (19.6) | 10 (22.2) | 8 (17.8) |
| >200–350 | 27 (51.9) | 32 (62.7) | 18 (40) | 21 (46.7) |
| >350 | — | — | 15 (33.3) | 15 (33.3) |
| WHO clinical staging (%) | ||||
| I | 30 (57.7) | 36 (70.6) | 26 (56.5) | 22 (46.8) |
| II | 10 (19.2) | 6 (11.8) | 6 (13.0) | 12 (25.5) |
| ≥III or IV | 12 (23.1) | 9 (17.6) | 14 (30.4) | 13 (27.7) |
| ART regimen (%) | ||||
| AZT + 3TC + EFVb | 19 (36.5) | 15 (29.4) | 9 (19.6) | 11 (23.4) |
| AZT + 3TC + NVPc | 28 (53.8) | 31 (60.8) | 26 (56.5) | 23 (48.9) |
| Other | 5 (9.6) | 5 (9.8) | 11 (23.9) | 13 (27.7) |
a1 USD = 6.36 CNY; b,cAZT: Zidovudine; 3TC: Lamivudine; NVP: Nevirapine; EFV: Efavirenz; ART: antiretroviral therapy.